| Verified against primary record | |
| Programme criteria | A published set of criteria, including evidence from randomised trials that the programme reduces mortality or morbidity[1] |
|---|---|
| Harm requirement | Benefits must outweigh harms including overdiagnosis, overtreatment and false positives[1] |
| Records read | National screening criteria and the systematic review record, 30 September 2026 |
| Independently reported | |
| General health checks | Little or no effect on total mortality, relative risk 1.00, 251,891 participants[2] |
| Bands apply only to the rows beneath them. The systematic review concerns systematic general health checks, not packages bought by self-selected purchasers. | |
Health screening abroad refers to comprehensive check-up packages sold to travelling patients, a substantial product in several Asian medical travel markets and marketed elsewhere as an executive health check. The word screening does a lot of work in that marketing, and the useful thing an encyclopedia can do is set the product against what the word means in public health.
What a screening programme has to satisfy
National screening programmes are appraised against published criteria, which in the United Kingdom are based on the criteria published by Wilson and Jungner for the World Health Organization in 1968.[3] The current criteria run to twenty and are grouped under the condition, the test, the intervention, the programme, and implementation.[1]
The condition must be an important health problem judged by frequency or severity, and cost-effective primary prevention must already have been implemented as far as practicable. The test must be simple, safe, precise and validated, with a known distribution of values in the target population, an agreed cut-off, acceptability to the target population from sample collection to delivery of results, and an agreed policy on diagnostic follow-up and the choices open to someone with a positive result. There must be an effective intervention for the patients the test identifies, and agreed evidence-based policies on who is offered it.[1]
Three criteria about the programme itself carry most of the weight. There must be evidence from high-quality randomised controlled trials that the programme reduces mortality or morbidity. It must be clinically, socially and ethically acceptable to health professionals and the public. And its benefits must outweigh any harms, for example from overdiagnosis, overtreatment and false positives, while offering value for money on cost-effectiveness analysis.[1]
This is the heart of the matter. A commercially sold package is a product bought by an individual. A screening programme is a population intervention that has had to demonstrate, before being offered to anybody, that it does more good than harm. Commercial packages are not appraised against these criteria, and nothing about being comprehensive substitutes for that appraisal. More tests is not a stronger version of screening; it is a different thing wearing the word.
What the evidence on check-ups shows
The most directly relevant evidence concerns general health checks in adults. A systematic review published in January 2019 included 17 randomised trials, 15 of them reporting outcome data, covering 251,891 participants. It found that health checks have little or no effect on total mortality, with a risk ratio of 1.00 and a 95 per cent confidence interval of 0.97 to 1.03 across 11 trials and 233,298 participants, assessed as high-certainty evidence. Cardiovascular mortality showed a risk ratio of 1.05 with an interval of 0.94 to 1.16 at moderate certainty, and cancer mortality a risk ratio of 1.01 with an interval of 0.92 to 1.12 across 8 trials at high certainty. The plain-language conclusion is that systematic offers of health checks are unlikely to be beneficial and may lead to unnecessary tests and treatments.[2]
One limit should be kept in view. Those trials studied systematic offers of health checks to defined populations, not packages purchased by people who chose to buy them and travelled to do so. The population is not identical, and the review should not be stretched to cover the commercial product directly. What it does establish, at high certainty and across a quarter of a million participants, is that the general proposition behind the product, that checking more things in well people saves lives, has been tested and did not hold.
No national body’s position specifically on commercially sold screening packages was located for this entry.
See also
- Diagnostic tourism, testing prompted by a clinical question rather than sold as a package
- Wellness tourism, the adjacent category this product is often sold alongside
- Longevity tourism, which markets a similar proposition to well people
- Medical tourism and public health, for the population-level view
References
- UK National Screening Committee. Criteria for appraising the viability, effectiveness and appropriateness of a screening programme. Published 20 October 2016, last updated 29 September 2022. Verified against primary record: official criteria publication opened and read. The implementation criteria were summarised rather than transcribed and are described in general terms here. Retrieved 30 September 2026.
- Krogsboll LT, Jorgensen KJ, Gotzsche PC. General health checks in adults for reducing morbidity and mortality from disease. Cochrane Database of Systematic Reviews, 2019, issue 1; published 30 January 2019. Verified against primary record: the publisher’s own record of the review opened and read; the full text was not reached. Retrieved 30 September 2026.
- UK National Screening Committee. Principles of screening. Last updated 11 July 2025. Verified against primary record: official guidance opened and read. Retrieved 30 September 2026.
Sourcing note: the screening criteria, the principles guidance and the systematic review record were opened and read on 30 September 2026. The criteria are described in substance; the implementation criteria were returned as a summary rather than as text and are therefore characterised in general terms rather than listed. The systematic review’s scope is stated, because it studied systematic offers to populations rather than packages bought by self-selected purchasers, and stretching it to cover the commercial product directly would overstate it.